Market Newsdesk

June 29, 2021 4:09 pm

SiriusXM to Launch Special Series Highlighting the People and Stories Behind the Historic Rebuilding of the New World Trade Center

“Top of the World” will premiere July 6 on Business Radio channel 132, as the 11-part weekly series builds towards the 20th anniversary of 9/11

Produced by MuddHouse Media, the series will feature WTC developer Larry Silverstein, WTC Master Planner Daniel Libeskind, former New York City Mayor Michael Bloomberg and others

PR Newswire

NEW YORK, June 29, 2021 /PRNewswire/ — SiriusXM today announced the launch of Top of the World: Lessons from Rebuilding the World Trade Center, an 11-part series featuring the people at the heart of the historic rebuilding of the new World Trade Center. The special programming will premiere July 6 on Business Radio channel 132, and will broadcast for 11 consecutive weeks in the lead-up to the 20th anniversary of the 9/11 attacks.

Each week Top of the World will explore the rebuilding through the eyes of those at the center of the action. These individuals will share lessons learned from the recovery after 9/11, the challenges Downtown Manhattan has faced throughout the last two decades, and the insights they’ve gathered about how the city and the country can better recover and rebuild after the pandemic.

Among the major figures featured throughout the series are World Trade Center developer Larry Silverstein; former New York City Mayor Michael Bloomberg; WTC Master Planner Daniel Libeskind; National 9/11 Memorial architect Michael Arad; the architects and engineers behind the new World Trade Center office towers; Downtown Manhattan business and community leaders; the artists, filmmakers and photographers who have captured and documented the historic rebuilding effort; and many more. Celebrity interviews offering support for the revitalization of Lower Manhattan will be interspersed throughout the series, as well.

“Rebuilding the World Trade Center has been – and continues to be – the passion of my life,” said Larry A. Silverstein, Chairman, Silverstein Properties. “As we approach the 20th anniversary of the 9/11 attacks, it is important to reflect on our collective mission to restore, revitalize, and re-invent Downtown Manhattan, and examine how the lessons we learned can inform our response to the devastation wrought by the tragedy of the pandemic.”

Top of the World will premiere on Business Radio at 7:00pm ET on July 6, with all episodes becoming available as podcasts on Pandora and Stitcher on September 6. The special series was created in collaboration with Silverstein Properties and MuddHouse Media. Click here to watch a trailer, see photos, and find out more details about the new special.

The episodes include:

Larry Silverstein, World Trade Center developer

Larry Silverstein purchased the Twin Towers at the age of 70 on July 24, 2001, only to see the complex destroyed in the 9/11 terror attacks. He has devoted the rest of his life to rebuilding the Trade Center. Despite many major obstacles over the past two decades, he has convinced some of the world’s leading companies to move into his new office buildings, and helped transform Lower Manhattan into a vibrant live-work neighborhood. A year into the pandemic that has temporarily brought the neighborhood, the city and the country to a halt, Silverstein reflects on his experience, and the road to recovery for New York and the nation.

Daniel Libeskind, WTC Master Plan architect
How do you rebuild a city within a city after the devastation of the worst terror attacks on American soil? Architect Daniel Libeskind won a star-studded international competition to lead the design process for the world’s most emotionally charged site. He talks about what inspired him as a young immigrant to the United States, the enormous challenges he faced, the magnificent place he created, and how it can help shape the future of cities in a post-pandemic world.

New York City Mayor Michael Bloomberg

Michael Bloomberg was sworn in as Mayor of New York City just four months after 9/11, and for the next 12 years, he oversaw much of the area’s and the city’s remarkable recovery. He was one of the earliest proponents of Downtown’s transformation from a 9-5 business center into a vibrant mixed-use 24/7 neighborhood. Mayor Bloomberg shares his thoughts on how the city can recover from the pandemic, and the lessons we can draw from the World Trade Center rebuilding.

Mary Ann Tighe, CEO of CBRE’s New York Tri-State Region
Over 15 million square feet of New York’s newest office space were destroyed on 9/11, forcing a mass exodus of office tenants from Downtown to other parts of the city. Mary Ann Tighe talks about what it took to convince companies to return to the new World Trade Center, and how the area became the media, communications and technology capital of New York, home to Condé Nast, Spotify and Uber, as well as luxury brands including Moet Hennessy and Diageo. She discusses the future of office space after more than a year of working remotely, and what the recovery from the pandemic means for the World Trade Center, Downtown Manhattan and cities across America.

Sean Johnson, Carlos Valverde, and Duan He, 3 WTC project executives; Michiko Ashida, 4 WTC design director
The people who built the new office towers for Larry Silverstein offer a behind-the-scenes look at the design, engineering and construction challenges of overseeing 3,000 daily construction workers build a $20 billion project in the heart of America’s oldest and most iconic business district. They discuss the sustainable design and security features in the new buildings, and how their work inspired high-rise design and construction all over the world.

Jessica Lappin and Catherine McVay Hughes

Jessica Lappin, President of the Alliance for Downtown New York, and Catherine McVay Hughes, a 33-year resident of Lower Manhattan and former chair of Manhattan Community Board One discuss their experience living and working in Lower Manhattan as their community recovered from the 9/11 attacks. They talk about the challenges of attracting new companies, businesses, residents and visitors back to the area, and offer insight on how Downtown can recover from the pandemic, and once again become one of the most popular, successful 24/7, mixed-use neighborhoods in the country.

Joe Woolhead, WTC photographer, “Once More to the Sky,” Judith Dupré, author, “One World Trade Center,” Mike Marcucci, producer, “16 Acres,” Grace Capobianco, publisher, “Downtown” magazine
As the unofficial chroniclers of the World Trade Center rebuilding, Joe Woolhead, Judith Dupré and Mike Marcucci talk about the obstacles and highlights of documenting – through film, photography and books – the 16-acre site on a daily basis over the past 20 years, and what is next for New York City. They are joined by Grace Capobianco who has been reporting on the rebirth of Lower Manhattan for 20 years.

Leslie Koch, President, Perelman Center for the Performing Arts

Leslie Koch offers a guided tour of the under-construction performing arts center, which will be the next building to open at the WTC site. She discusses the importance of arts and culture to Lower Manhattan and to a city that is just now beginning to recover from the pandemic. We witness the very first musical performance in the new building with violinist Gregory Harrington and cellist Eleanor Norton.

Kerry Irvine, Joohee Park, Lady Aiko, Risa Boogie, Cristina Martinez, Komikka Patton
Before any companies moved into the new World Trade Center towers, a small group of artists set up makeshift studios in raw space overlooking the site. From this rare perch, they began to capture and document the massive construction project below. These artists tell their personal stories of passion, hope, renewal and perseverance from their studios in the sky, and the important role that art and creativity continues to play in Lower Manhattan.

Robert Whitlock, KPF; Maria Masi, Brookfield Properties; Marty Burger, Silverstein Properties; Dawanna Williams, Dabar Development Partners
Architect Robert Whitlock, and developers Maria Masi, Marty Burger and Dawanna Williams talk about 5 WTC, the only residential tower proposed for the WTC site. Featuring 1,325 apartments, including 330 that will be permanently affordable, this will be the country’s most significant and anticipated energy efficient and sustainable apartment building when it opens in 2026.

Michael Arad, 9/11 Memorial architect
How do you create a place of remembrance in the heart of a bustling city? Michael Arad was a young, unknown architect when he beat out 5,200 others to win a competition to design the National 9/11 Memorial at the World Trade Center. He talks about what inspired him, changes he was forced to make to his design, the opening of the Memorial on the 10th anniversary of 9/11, and his thoughts on a national memorial to the victims of Covid-19.

Video and audio trailers, and photos can be found here:

About MuddHouse Media

MuddHouse Media is a company composed of diversified knowledge and skill sets, specializing in the most niche and mainstream facets of science, sports, comedy, lifestyles and culture, music and art, business, entrepreneurship, and much more. MuddHouse Media combines niche expertise to create compelling, engaging and appealing storytelling. It presents the most passionate individuals discussing the subjects they live for, with people who either share their zest or can offer a novel or unique take or opinion on the subject. Its offering includes full-service production of original podcasts, corporate podcasts, and media and scripted podcast series. MuddHouse Media original series include “Being American,” with former Massachusetts Governor Deval Patrick; “Tanya’s Table,” with chef Tanya Holland; “Holding Court,” with tennis analyst and former professional player Patrick McEnroe; and “Saints, Sinners and Serial Killers,” hosted by New York Times best-selling authors Casey Sherman and Dave Wedge. MuddHouse Media has created podcasts for leaders in their fields including “The Sound Experience” with Panasonic Automotive, “Bring Out the Talent” with The Training Associates, and Bruker Industries. Like us on Facebook, follow us on Instagram, like us on Twitter, connect with us on LinkedIn. For more information, visit us at www.muddhousemedia.com.

About Silverstein Properties

Silverstein Properties is a privately held, full-service real estate development, investment and management firm based in New York. Founded in 1957 by Chairman Larry Silverstein, the company has developed, owned and managed more than 40 million square feet of commercial, residential, retail and hotel space. Recent projects include 7 World Trade Center, the first LEED-certified office tower in New York City (2006), 4 World Trade Center (2013), Four Seasons Walt Disney Resort (2014), the Four Seasons Downtown and 30 Park Place (2016), One West End (2017), and 3 World Trade Center (2018). For further information on Silverstein Properties, please visit www.silversteinproperties.com or www.wtc.com.

About SiriusXM

Sirius XM Holdings Inc. (NASDAQ: SIRI) is the leading audio entertainment company in North America, and the premier programmer and platform for subscription and digital advertising-supported audio products. Pandora, a subsidiary of SiriusXM, is the largest ad-supported audio entertainment streaming service in the U.S. SiriusXM’s properties, which include Pandora and leading podcast company Stitcher, reach more than 150 million listeners, the largest addressable audience in the U.S., across all categories of digital audio – music, sports, talk, and podcasts. SiriusXM’s acquisitions of Stitcher and Simplecast, alongside industry-leading ad tech company AdsWizz, make it a leader in podcast hosting, production, distribution, analytics and monetization. SiriusXM, through Sirius XM Canada Holdings, Inc., also offers satellite radio and audio entertainment in Canada. In addition to its audio entertainment businesses, SiriusXM offers connected vehicle services to automakers. For more about SiriusXM, please go to: www.siriusxm.com.

Media contact for Silverstein Properties:

Dara McQuillan

[email protected]

212-551-7352

Media contacts for SiriusXM:

Danielle Lynn

[email protected]

Chelsea Kaufman

[email protected]

View original content:https://www.prnewswire.com/news-releases/siriusxm-to-launch-special-series-highlighting-the-people-and-stories-behind-the-historic-rebuilding-of-the-new-world-trade-center-301322463.html

SOURCE Silverstein Properties; SiriusXM

June 29, 2021 4:09 pm

BNY Mellon Municipal Bond Closed-End Funds Declare Distributions

BNY Mellon Municipal Bond Closed-End Funds Declare Distributions

NEW YORK–(BUSINESS WIRE)–
BNY Mellon Investment Adviser, Inc. announced today that BNY Mellon Municipal Income, Inc., BNY Mellon Strategic Municipal Bond Fund, Inc. and BNY Mellon Strategic Municipals, Inc. (each, a “Fund”) have declared a monthly distribution for each Fund’s common shares as summarized below. The distributions are payable on July 30, 2021 to shareholders of record on July 15, 2021, with an ex-dividend date of July 14, 2021.

Fund	Ticker	Monthly Distribution Per Share	Change from Prior Monthly Distribution Per Share
BNY Mellon Municipal Income, Inc.	DMF	$0.035	—
BNY Mellon Strategic Municipal Bond Fund, Inc.	DSM	$0.030	—
BNY Mellon Strategic Municipals, Inc.	LEO	$0.035	—

Important Information

BNY Mellon Investment Adviser, Inc., the investment adviser for the Fund, is part of BNY Mellon Investment Management. BNY Mellon Investment Management is one of the world’s largest asset managers, with $2.2 trillion in assets under management as of March 31, 2021. Through an investor-first approach, BNY Mellon Investment Management brings to clients the best of both worlds: specialist expertise from eight investment firms offering solutions across every major asset class, backed by the strength, stability, and global presence of BNY Mellon. Additional information on BNY Mellon Investment Management is available on www.bnymellonim.com.

BNY Mellon Investment Management is a division of BNY Mellon, which has $41.7 trillion in assets under custody and/or administration as of March 31, 2021. BNY Mellon can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute or restructure investments. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK). Additional information is available on www.bnymellon.com. Follow us on Twitter @BNYMellon or visit our newsroom at www.bnymellon.com/newsroom for the latest company news.

Closed-end funds are traded on the secondary market through one of the stock exchanges. The Fund investment returns and principal values will fluctuate so that an investor’s shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the fund’s portfolio. There is no assurance that the Fund will achieve its investment objective.

This release is for informational purposes only and should not be considered as investment advice or a recommendation of any particular security.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210629006034/en/

For Press Inquiries:

BNY Mellon Investment Adviser, Inc.

Benjamin Tanner

(212) 635-8676

For Other Inquiries:

BNY Mellon Securities Corporation

The National Marketing Desk

240 Greenwich Street

New York, New York 10286

1-800-334-6899

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo

June 29, 2021 4:08 pm

Dynavax Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

EMERYVILLE, Calif., June 29, 2021 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that, in connection with the appointment of John Slebir as Senior Vice President, General Counsel on June 28, 2021, the Company granted him a non-statutory stock option to purchase 300,000 shares of Dynavax common stock.

The stock option has a 7-year term and vests over three years, with one-third of the shares underlying the option vesting on the one-year anniversary of the grant date, and the remaining shares vesting 1/36 per month in equal installments, subject to Mr. Slebir’s continued service with Dynavax through the applicable vesting dates. The stock option was granted with an exercise price of $9.29 per share, which is equal to the closing price of Dynavax common stock on the date of grant, and was provided as a material inducement to Mr. Slebir’s employment in accordance with Nasdaq Listing Rule 5635(c)(4). The option is subject to the terms and conditions of a stock option agreement covering the grant and Dynavax’s 2021 Inducement Award Plan, which was adopted on January 9, 2021 and provides for the granting of stock options to new employees.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company’s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Dynavax Contacts:

Nicole Arndt, Senior Manager, Investor Relations
[email protected]
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-301322461.html

SOURCE Dynavax Technologies

June 29, 2021 4:08 pm

Riley Exploration Permian, Inc. Announces Proposed Public Offering of Common Stock

PR Newswire

OKLAHOMA CITY, June 29, 2021 /PRNewswire/ — Riley Exploration Permian, Inc. (NYSE American: REPX) (“Riley Permian” or the “Company”) announced today that it has commenced an underwritten public offering of shares of its common stock (the “Offering”). The Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the Offering. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.

The Company intends to use approximately $25 million of the net proceeds from the Offering to accelerate its enhanced oil recovery (“EOR”) pilot program, including funding capital expenditures related to drilling, completions and infrastructure. The EOR pilot program encompasses a 960-acre project area in Yoakum County, Texas, and will apply water and CO₂ through vertical injection wells adjacent to horizontal producing wells, with the goal of using anthropogenic CO₂ (“ACO₂“). The Company intends to use the remaining net proceeds from the Offering for general corporate purposes, including, but not limited to, financing of capital expenditures, financing acquisitions or investments, repaying or refinancing of outstanding debt, financing other business opportunities, and working capital purposes.

Truist Securities is acting as sole book-running manager for the Offering.

The Offering will be made only by means of a prospectus supplement and the accompanying base prospectus filed as part of an effective shelf registration statement filed with the Securities and Exchange Commission (“SEC”) on Form S-3. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the Offering, as well as copies of the final prospectus supplement, once available, may be obtained on the SEC’s website at www.sec.gov or by contacting Truist Securities, Inc., Attention: Prospectus Department, 3333 Peachtree Road NE, 9th floor, Atlanta, Georgia 30326, [email protected].

This press release does not constitute an offer to sell, a solicitation to buy or an offer to purchase or sell any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Riley Exploration Permian, Inc.
Riley Permian is an independent oil and natural gas company focused on steadily growing its reserves, production and cash flow per share through the acquisition, exploration, development and production of oil, natural gas, and natural gas liquids in the Permian Basin. For more information please visit www.rileypermian.com.

CAUTIONARY STATEMENT FOR THE PURPOSES OF THE “SAFE HARBOR” PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains forward-looking statements regarding future events and future results that are subject to the safe harbors created under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including, but not limited to, statements regarding the Company’s plans to issue the common stock and the anticipated use of the net proceeds from the Offering. When used in this press release, forward-looking statements are generally accompanied by terms or phrases such as “estimate,” “project,” “predict,” “believe,” “expect,” “continue,” “anticipate,” “target,” “could,” “plan,” “intend,” “seek,” “goal,” “will,” “should,” “may” or other words and similar expressions that convey the uncertainty of future events or outcomes. Items contemplating or making assumptions about actual or potential future production and sales, market size, collaborations, and trends or operating results also constitute such forward-looking statements.

Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond the Company’s control) that could cause actual results to differ materially from those set forth in the forward looking statements, including fluctuations in the price we receive for our oil, gas, and NGL production, including local market price differentials; the impact of the COVID-19 pandemic, including reduced demand for oil and natural gas, economic slowdown, governmental and societal actions taken in response to the COVID-19 pandemic, and stay-at-home orders or illness that may cause interruptions to our operations; cost and availability of gathering, pipeline, refining, transportation and other midstream and downstream activities and our ability to sell oil, gas, and NGLs, which may be negatively impacted by the COVID-19 pandemic; severe weather and other risks and lead to a lack of any available markets; risks related to our recently completed merger, including challenges associated with integrating operations and diversion of management’s attention to merger-related issues; our ability to successfully complete mergers, acquisitions and divestitures; the risk that the Company’s EOR project may not perform as expected or produce the anticipated benefits; risks relating to our operations, including development drilling and testing results and performance of acquired properties and newly drilled wells; any reduction in our borrowing base from time to time and our ability to repay any excess borrowings as a result of such reduction; the impact of our derivative instruments and hedging activities; continuing compliance with the financial covenants contained in our credit agreement; the loss of certain federal income tax deductions; risks associated with executing our business strategy, including any changes in our strategy; inability to prove up undeveloped acreage and maintaining production on leases; risks associated with concentration of operations in one major geographic area; deviations from our forecasts and budgets, including our 2021 capital expenditure budget; the ability of the members of the Organization of Petroleum Exporting Countries (“OPEC”) and other oil exporting nations to agree to, adhere to and maintain oil price and production controls; legislative or regulatory changes, including initiatives related to hydraulic fracturing, emissions, and disposal of produced water, which may be negatively impacted by the recent change in Presidential administration or legislatures; the ability to receive drilling and other permits or approvals and rights-of-way in a timely manner (or at all), which may be negatively impacted by the impact of COVID-19 restrictions on regulatory employees who process and approve permits, other approvals and rights-of-way and which may be restricted by new Presidential and Secretarial orders and regulation and legislation; risks related to litigation; and cybersecurity threats, technology system failures and data security issues.

Additional factors that could cause results to differ materially from those described above can be found in the preliminary prospectus supplement and prospectus supplement and base prospectus related to the Offering, Riley Permian’s Annual Report on Form 10-K for the year ended December 31, 2020 and in its subsequently filed Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021, each of which is on file with the SEC and available from the Company’s website at www.rileypermian.com under the “Investor” tab.

The Company has based these forward-looking statements on its current expectations and assumptions about future events. While management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond the Company’s control. You are urged not to place undue reliance on these forward–looking statements, which speak only as of the date they are made. The forward-looking statements in this press release are made as of the date hereof and are based on information available at that time. Except as may be required by applicable law or regulation, the Company does not undertake, and expressly disclaims, any duty to update or revise our forward-looking statements based on new information, future events or otherwise.

Philip Riley

Executive Vice President, Strategy
[email protected]
(405) 438-0126

Source: Riley Exploration Permian, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/riley-exploration-permian-inc-announces-proposed-public-offering-of-common-stock-301322462.html

SOURCE Riley Exploration Permian, Inc.

June 29, 2021 4:08 pm

Motus GI to Present at the Ladenburg Thalmann Healthcare Conference

FORT LAUDERDALE, Fla., June 29, 2021 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to present at the upcoming Ladenburg Thalmann Healthcare Conference begin held from July 13 to July 14.

Ladenburg Thalmann Healthcare Conference
Presentation:	Tuesday, July 13, 2021, at 3:30 p.m. Eastern Time
Webcast:	The presentation will be accessible via a live webcast at
	https://wsw.com/webcast/ladenburg7/mgh/2203060.

	The webcast will be archived on the Events page on the Company’s website, www.motusgi.com.

About Motus GI Holdings, Inc.

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions. For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms, including without limitation, risks related to the Company’s cost reduction plan, the cost savings and the cash expenses related to the implementation of the plan, risks related to the continued impact of the COVID-19 pandemic, risks inherent in the development and commercialization of potential products, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s Form 10-K filed on March 16, 2021, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:

Bob Yedid
LifeSci Advisors
(646) 597-6989
[email protected]

June 29, 2021 4:08 pm

SeaSpine to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference

CARLSBAD, Calif., June 29, 2021 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the Company will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July 13, 2021, beginning at 10:30 AM ET.

A live and archived webcast of the event will be available from the Investor Relations page of the Company’s website at investor.seaspine.com.

About SeaSpine

SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences, as well as spinal implants, software, and advanced optics product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

Investor Relations Contact

Leigh Salvo
(415) 937-5402
[email protected]

June 29, 2021 4:08 pm

Bank OZK Announces Date for Second Quarter 2021 Earnings Release and Conference Call

LITTLE ROCK, Ark., June 29, 2021 (GLOBE NEWSWIRE) — Bank OZK (the “Bank”) (Nasdaq: OZK) expects to report second quarter 2021 earnings after the market closes on Thursday, July 22, 2021. Management’s comments on the second quarter of 2021 will be released simultaneously with the earnings press release and will be available on the Bank’s investor relations website.

Management will conduct a conference call to take questions at 10:00 a.m. CT (11:00 a.m. ET) on Friday, July 23, 2021. Interested parties may listen to this call by dialing 1-844-818-5110 (U.S. and Canada) or 210-229-8841 (international) and asking for the Bank OZK conference call. A recorded playback of the call will be available for one week following the call at 1-855-859-2056 (U.S. and Canada) or 404-537-3406 (international). The passcode for this playback is 3462545. The call will be available live or in a recorded version on the Bank’s investor relations website ir.ozk.com under Q1 Earnings Conference Call Webcast.

GENERAL INFORMATION

Bank OZK (Nasdaq: OZK) is a regional bank providing innovative financial solutions delivered by expert bankers with a relentless pursuit of excellence. Established in 1903, Bank OZK conducts banking operations through 250 offices in eight states including Arkansas, Georgia, Florida, North Carolina, Texas, New York, California and Mississippi and had $27.28 billion in total assets as of March 31, 2021. Bank OZK can be found at www.ozk.com and on Facebook, Twitter and LinkedIn or contacted at (501) 978-2265 or P.O. Box 8811, Little Rock, Arkansas 72231-8811.

The Bank files annual, quarterly and current reports, proxy materials, and other information required by the Securities Exchange Act of 1934 with the Federal Deposit Insurance Corporation (“FDIC”), copies of which are available electronically at the FDIC’s website at https://efr.fdic.gov/fcxweb/efr/index.html and are also available on the Bank’s investor relations website at ir.ozk.com. To receive automated email alerts for these materials please visit https://ir.ozk.com/other/email-notification/default.aspx to sign up.

Investor Relations Contact:	Tim Hicks, (501) 978-2336
Media Contact:	Susan Blair, (501) 978-2217

June 29, 2021 4:08 pm

Kura Sushi USA to Announce Fiscal Third Quarter 2021 Financial Results on Tuesday, July 13, 2021

IRVINE, Calif., June 29, 2021 (GLOBE NEWSWIRE) — Kura Sushi USA, Inc. (“Kura Sushi” or the “Company”), (NASDAQ: KRUS), a technology-enabled Japanese restaurant concept, today announced that it will host a conference call to discuss fiscal third quarter 2021 financial results on Tuesday, July 13^th, 2021 at 5:00 p.m. ET. A press release with fiscal third quarter 2021 financial results will be issued that same day after the market closes. Hosting the conference call and webcast will be Hajime “Jimmy” Uba, President and Chief Executive Officer, and Steven Benrubi, Chief Financial Officer.

Interested parties may listen to the conference call via telephone by dialing 201-689-8471. A telephone replay will be available shortly after the call has concluded and can be accessed by dialing 412-317-6671; the passcode is 13720825.

The webcast will be available at www.kurasushi.com under the Investor Relations section and will be archived on the site shortly after the call has concluded.

About Kura Sushi USA, Inc.

Kura Sushi USA, Inc. is a technology-enabled Japanese restaurant concept with 32 locations in nine states and Washington DC. The Company offers guests a distinctive dining experience built on authentic Japanese cuisine and an engaging revolving sushi service model. Kura Sushi USA, Inc. was established in 2008 as a subsidiary of Kura Sushi, Inc., a Japan-based revolving sushi chain with over 450 restaurants and 35 years of brand history. For more information, please visit www.kurasushi.com.

Investor Relations Contact:
Fitzhugh Taylor
(657) 333-4010
[email protected]

June 29, 2021 4:08 pm

Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Topline results for Phase 3 Pivotal Cardigan I and Cardigan II studies expected in Q4 2021

BOULDER, Colo., June 29, 2021 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that the final patient has completed the Phase 3 pivotal Cardigan I study, and that all planned patients have been enrolled in the Phase 3 pivotal Cardigan II study. Both studies are evaluating sofpironium bromide gel, 15% in patients with primary axillary (underarm) hyperhidrosis.

“This is truly an exciting time for the Brickell team, as we have now completed enrollment in both of our Phase 3 pivotal clinical studies of sofpironium bromide gel, 15%. Also, since completing enrollment in the Cardigan I study in April, the last hyperhidrosis patient enrolled has completed the study,” said Deepak Chadha, Chief Research and Development Officer of Brickell. “On behalf of Brickell, I want to take this opportunity to thank the patients and investigators who participated in the Cardigan I study, as well as those currently participating in the Cardigan II study. We remain focused on completing the Cardigan II study as planned and reporting topline results from the Phase 3 program in the fourth quarter of 2021. We look forward to sharing updates on the progress of the Phase 3 pivotal clinical studies over the coming months.”

U.S. Phase 3 Cardigan I and Cardigan II Studies

Brickell’s U.S. Phase 3 clinical program for sofpironium bromide gel, 15% is comprised of two pivotal clinical studies, Cardigan I and Cardigan II. Each study has enrolled approximately 350 subjects nine years of age and older with primary axillary hyperhidrosis. The studies are multicenter, randomized, double-blinded, vehicle (placebo)-controlled studies evaluating the efficacy and safety of topically applied sofpironium bromide gel, 15%. Subjects will apply sofpironium bromide gel, 15% or placebo to their underarms once daily at bedtime for 6 consecutive weeks, with a 2-week post-treatment follow-up. The co-primary efficacy endpoints of both studies include the proportion of subjects achieving at least a 2-point improvement on the Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) scale, a proprietary and validated patient-reported outcome measure, and change in gravimetric sweat production (GSP), each from baseline to end of treatment. Safety and tolerability assessments will be performed throughout the studies.

The Company expects to announce topline results from the Cardigan I and Cardigan II clinical studies in the fourth quarter of 2021. If successful, the results from the studies are expected to form the basis of a prospective New Drug Application (NDA) in the U.S. for sofpironium bromide gel, 15% for the treatment of primary axillary hyperhidrosis. Additional details of the Cardigan I and II studies can be found on https://clinicaltrials.gov under identifiers NCT03836287 and NCT03948646, respectively.

About Sofpironium Bromide

Sofpironium bromide is Brickell’s lead investigational product candidate and is a new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are intended to exert their action locally and are potentially rapidly metabolized into a less active metabolite once absorbed into the blood. Sofpironium bromide gel, 15% is currently being evaluated in a U.S. pivotal Phase 3 clinical program for the treatment of primary axillary hyperhidrosis, and sofpironium bromide gel, 5% is approved in Japan for the same indication under the brand name ECCLOCK^®. Sofpironium bromide was discovered at Bodor Laboratories, Inc. by Dr. Nicholas Bodor D.Sc., d.h.c. (multi), HoF, Graduate Research Professor Emeritus, University of Florida.

About Hyperhidrosis

Hyperhidrosis is a debilitating, life-altering medical condition where a person sweats beyond what is physiologically required for thermoregulation of the body. More than 15 million people, or 4.8% of the population of the United States, and 12.76% of the population in Japan, are believed to suffer from hyperhidrosis^1,2. Primary axillary (underarm) hyperhidrosis is the targeted first indication for sofpironium bromide and is the most common site of occurrence of hyperhidrosis, affecting an estimated 65% of patients with hyperhidrosis in the United States. Additional information can be found on the International Hyperhidrosis Society website: https://www.sweathelp.org/.

About Brickell

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis^®, Taltz^®, Gemzar^®, Prozac^®, Cymbalta^® and Juvederm^®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs. For more information, visit https://www.brickellbio.com.

Cautionary Note Regarding Forward-Looking Statements

Any statements made in this press release relating to future financial, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, the anticipated timing, scope, design and/or results of ongoing and future clinical trials, intellectual property rights, including the validity, term and enforceability of such, the expected timing and/or results of regulatory approvals and prospects for commercializing any of Brickell’s product candidates, or research collaborations with its partners, including in Japan, the United States or any other country, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict,” “potential,” “look forward” and similar expressions and their variants, as they relate to Brickell, Kaken, or any of Brickell’s partners, may identify forward-looking statements. Brickell cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, ability to obtain adequate financing to advance product development, ability to maintain and enforce intellectual property rights, potential delays for any reason in product development and clinical trial enrollment, regulatory changes, supply chain disruptions, unanticipated demands on cash resources, any disruption to its business caused by the current COVID-19 pandemic, interruptions, disruption or inability by Kaken to supply and commercialize the product in Japan, or obtain or retain adequate pricing or reimbursement, the outcome of Brickell’s ongoing U.S. Phase 3 pivotal program on sofpironium bromide, and other risks associated with developing and obtaining regulatory approval for and commercializing product candidates.

Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Brickell’s filings with the United States Securities and Exchange Commission (SEC), which are available at https://www.sec.gov (or at https://www.brickellbio.com). The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.

____________________

¹ Doolittle et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016; 308: 743-749.
² Fujimoto et al. Epidemiological study and considerations of focal hyperhidrosis in Japan. J Dermatol 2013; 40: 886-90.

Brickell Investor Contact:

Dan Ferry
LifeSci Advisors
(617) 430-7576
[email protected]

June 29, 2021 4:08 pm

AMMO, Inc. Reports Financial Results for its Fiscal Fourth Quarter and Full Fiscal Year

– Annual Adjusted EBITDA of $8.1 million and Adjusted EPS of $0.07 per share –

SCOTTSDALE, Ariz., June 29, 2021 (GLOBE NEWSWIRE) — AMMO, Inc. (Nasdaq: POWW, POWWP) (“AMMO” or the “Company”), a premier American ammunition and munition components manufacturer and technology leader, is pleased to announce it has reported financial results for its fiscal fourth quarter and year ending March 31, 2021.

Financial Summary for Fiscal
Fourth
Quarter 2021 v
s
. Fiscal
Fourth
Quarter 2020

Sales for the quarter were $24.2 million – an increase of 409%
Gross Profit Margins increased to approximately 23% – an increase of 179%
Operating expenses as a percentage of sales decreased 58%
Adjusted EBITDA increased to $4.8 million — an increase of 296%
Adjusted EPS increased to $0.04 – an increase of 167%

Financial Summary
for
Fiscal 2021 vs.
Fiscal
2020

Sales for the year increased to $62.5 million – an increase of 300%
Gross Profit Margins increased to approximately 18% — an increase of 173%
Operating expenses as a percentage of sales decreased 61%
Annual adjusted EBITDA increased to $8.1 million – an increase of 213%
Adjusted EPS Increased to $0.07 — an increase of 150%

AMMO is positioned for exceptional growth in Fiscal 2022 after establishing a new standard for the Company. Demand fundamentals in the US domestic ammunition market are exceedingly strong and we are seeing no indication of slowing. The Company broke ground on its new state-of-the-art plant, scheduled to be fully operational in approximately one year. And we have established the Company as a cutting-edge design firm, announcing a contract for the design and manufacture of technologically advanced ballistic match ammunition for the US Department of Defense. Our fiscal fourth quarter delivered the best quarterly performance in Company history, with even better quarters reasonably expected to follow throughout Fiscal 2022.

Additionally, the Company experienced sales growth of 46% quarter-over-quarter, a $7.6 million increase.

The Company’s margins have also increased to approximately 23% for our fourth fiscal quarter, an increase of 179% or $7.1 million year-over-year. When depreciation and amortization are added back to the cost of goods sold, our gross profit margin increases to 27% for the quarter.

Our operating expenses as a percentage of sales was 25%, representing a 58% decrease from the prior year quarter. For the year, our operating expense as a percentage of sales was 27%, a 61% decrease from the prior year.

Net Loss for the quarter was approximately $463,000, which includes approximately $3.4 million of non-cash expenses. Net Loss for the year was approximately $7.8 million, which also included $10.1 million in non-cash expenses.

Adjusted EBITDA has grown to $4.8 million for the quarter – 296% increase from the prior year. For the year, our Adjusted EBITDA was $8.1 million – 213% increase from the prior year.

The continuing improvement in adjusted EBITDA and margin shows the impact of the scaling we are beginning to see in our operational costs. We expect our first half fiscal 2022 EBITDA to be better than the second half of fiscal 2021 as a standalone.

AMMO’s adjusted earnings per share (EPS) increased to $0.04 for our fiscal fourth quarter, representing a 167% year-over-year increase. Our adjusted EPS increased to $0.07 for the year, representing a 150% increase from the prior year. Adjusted EPS is a metric the Company values as we believe it is a better representation of the Company’s true operating performance.

The revenue guidance for the 1st quarter of our 2022 Fiscal Year is $41M and will include two months of operations from our newly acquired Gunbroker.com assets. As previously announced, we expect to achieve profitability in this quarter.

Non-GAAP Financial Measures

We analyze operational and financial data to evaluate our business, allocate our resources, and assess our performance. In addition to total net sales, net loss, and other results under generally accepted accounting principles (GAAP), the following information includes key operating metrics and non-GAAP financial measures we use to evaluate our business. We believe these measures are useful for period-to-period comparisons of the Company. We have included these non-GAAP financial measures in this Quarterly Report on Form 10-Q because they are key measures we use to evaluate our operational performance, produce future strategies for our operations, and make strategic decisions, including those relating to operating expenses and the allocation of our resources. Accordingly, we believe these measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.

Adjusted
EBITDA

	For the			For the
	Year Ended			Year Ended
	March 31, 2021			March 31, 2020

Reconciliation of GAAP net income to Adjusted EBITDA
Net (Loss)		(7,812,294	)		(14,556,680	)
Depreciation and amortization		4,876,756			4,455,962
Interest expense, net		3,009,094			719,187
Excise taxes		4,286,258			643,735
Employee stock awards		1,450,359			901,526
Stock grants		278,585			534,929
Stock for services		1,707,500			352,300
Contingent consideration fair value		(119,731	)		(190,377	)
Other income		(576,785	)		–
Loss on purchase		1,000,000			–
Adjusted EBITDA	$	8,099,742		$	(7,139,418	)

	For the Year Ended March 31, 2021						For the Year Ended March 31, 2020						For the Three Months Ended March 31, 2021						For the Three Months Ended March 31, 2020
Reconciliation of GAAP net income to Fully Dilutive Adjusted EPS⁽¹⁾⁽²⁾
Net (Loss)	$	(7,812,294	)	$	(0.13	)	$	(14,556,680	)	$	(0.27	)	$	(463,443	)	$	(0.01	)	$	(4,406,598	)	$	(0.10	)
Depreciation and amortization		4,876,756			0.08			4,455,962			0.08			1,287,790			0.02			1,498,625			0.03
Interest expense, net		3,009,094			0.05			719,187			0.01			304,779			0.00			111,477			0.00
Employee stock awards		1,450,359			0.02			901,526			0.02			733,770			0.01			212,776			0.00
Stock grants		278,585			0.00			534,929			0.01			65,455			0.00			(13,129	)		(0.00	)
Stock for services		1,707,500			0.03			352,300			0.01			1,620,000			0.02			80,300			0.00
Contingent consideration fair value		(119,731	)		(0.00	)		(190,377	)		(0.00	)		(31,625	)		(0.00	)		(190,377	)		(0.00	)
Other income		(576,785	)		(0.01	)		–			–			(302,385	)		(0.00	)		–			–
Loss on purchase		1,000,000			0.02			–			–			–			–			–			–
	$	3,813,484		$	0.07		$	(7,783,153	)	$	(0.14	)	$	3,214,341		$	0.04		$	(2,706,926	)	$	(0.06	)

(1) Fully Dilutive Weighted Shares Outstanding were 58,549,449 and 54,112,309, respectively for the years ended March 31, 2021 and 2020.

(2) Fully Dilutive Weighted Shares Outstanding were 72,598,171 and 45,970,236, respectively, for the three months ended March 31, 2021 and 2020.

Adjusted EBITDA is a non-GAAP financial measures that displays our net loss, adjusted to eliminate the effect of certain items as described below.

We have excluded the following non-cash expenses from our non-GAAP financial measures: depreciation and amortization, loss on purchase, share-based compensation expenses, and changes to the contingent consideration fair value. We believe it is useful to exclude these non-cash expenses because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations.

Adjusted EBITDA as a non-GAAP financial measure also excludes other cash interest income and expense, as these items are not components of our core operations. We have not included adjustment for any provision or benefit for income taxes as we currently record a valuation allowance and have included adjustment for excise taxes.

Non-GAAP financial measures have limitations, should be considered as supplemental in nature, and are not meant as a substitute for the related financial information prepared in accordance with GAAP. These limitations include the following:

Employee stock awards and stock grants expense has been, and will continue to be for the foreseeable future, a significant recurring expense in the Company and an important part of our compensation strategy;
The assets being depreciated or amortized may have to be replaced in the future, and the non-GAAP financial measures do not reflect cash capital expenditure requirements for such replacements or for new capital expenditures or other capital commitments;
Non-GAAP measures do not reflect changes in, or cash requirements for our working capital needs; and
Other companies, including companies in our industry, may calculate the non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures.

Because of these limitations, you should consider the non-GAAP financial measures alongside other financial performance measures, including our net loss and other financial results presented in accordance with GAAP.

About AMMO, Inc.

With its corporate offices headquartered in Scottsdale, Arizona. AMMO designs and manufactures products for a variety of aptitudes, including law enforcement, military, sport shooting and self-defense. The Company was founded in 2016 with a vision to change, innovate and invigorate the complacent munitions industry. AMMO promotes branded munitions as well as its patented STREAK^™ Visual Ammunition, /stelTH/^™subsonic munitions, and armor piercing rounds for military and law enforcement use. For more information, please visit: www.ammo-inc.com.

About GunBroker.com

As an AMMO subsidiary, GunBroker.com is the largest online marketplace dedicated to firearms, hunting, shooting and related products. Aside from merchandise bearing its logo, GunBroker.com currently sells none of the items listed on its website. Third-party sellers list items on the site and Federal and state laws govern the sale of firearms and other restricted items. Ownership policies and regulations are followed using licensed firearms dealers as transfer agents. Launched in 1999, GunBroker.com is an informative, secure and safe way to buy and sell firearms, ammunition, air guns, archery equipment, knives and swords, firearms accessories and hunting/shooting gear online. GunBroker.com promotes responsible ownership of guns and firearms. For more information, please visit: www.gunbroker.com.

Forward Looking Statements

This document contains certain “forward-looking statements”. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies, goals and objectives of management for future operations; any statements concerning proposed new products and services or developments thereof; any statements regarding future economic conditions or performance; any statements or belief; and any statements of assumptions underlying any of the foregoing.

Forward looking statements may include the words “may,” “could,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words, or the negative thereof. These forward-looking statements present our estimates and assumptions only as of the date of this report. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the dates on which they are made. We do not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the dates they are made. You should, however, consult further disclosures and risk factors we include in Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Reports filed on Form 8-K.

Reminder
–
Earnings Call

AMMO’s Fiscal 2021 Earnings Call is scheduled for Tuesday, June 29, 2021 (5:00 pm Eastern Time). To participate in the conference call, please join by dialing 1-877-407-0789 (domestic), 1-201-689-8562 (international), or via webcast (http://public.viavid.com/index.php?id=145369) at least 5-10 minutes prior to the scheduled start and follow the operator’s instructions. When requested, please ask for the “AMMO, Inc. Fiscal 2021 Earnings Call.”

Investor Contact:

Rob Wiley, CFO
AMMO, Inc.
Phone: (480) 947-0001
[email protected]